Gary Remington, MD, PhD, FRCPC

Original Research

An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis

March 8, 2011

Ofer Agid, Tamara Arenovich, Gautam Sajeev, et al

Original Research

"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial

September 7, 2010

Gary Remington, Philip Seeman, Alan Feingold, et al

Original Research

Treatment of Clozapine-Induced Hypersalivation With Ipratropium Bromide: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

August 15, 2009

Sanjeev Sockalingam, Chekkera Shammi, Gary Remington

Original Research

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

August 31, 2008

Hiroyuki Uchida, David C. Mamo, Shitij Kapur, et al

Original Research

Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label Trial of the First Long-Acting Second-Generation Antipsychotic

October 15, 2003

W. Wolfgang Fleischhacker, Mariëlle Eerdekens, Keith Karcher, et al

Letter to the Editor

Hyperinsulinemia in Psychiatric Patients Treated With Olanzapine

January 1, 2002

Tony A. Cohn, Gary Remington, Homa Kameh

Article

D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET

October 1, 1999

Gary Remington, Shitij Kapur

Letter to the Editor

Risperidone Treatment of Tardive Dyskinesia and Dystonia

May 1, 1999

Siow-Ann Chong, Gary Remington, Chay-Hoon Tan

Gary Remington, MD, PhD, FRCPC

An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis

"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial

Treatment of Clozapine-Induced Hypersalivation With Ipratropium Bromide: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label Trial of the First Long-Acting Second-Generation Antipsychotic

Hyperinsulinemia in Psychiatric Patients Treated With Olanzapine

D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET

Risperidone Treatment of Tardive Dyskinesia and Dystonia

ELSEWHERE:

FOLLOW US:

Gary Remington, MD, PhD, FRCPC

An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis

"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial

Treatment of Clozapine-Induced Hypersalivation With Ipratropium Bromide: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label Trial of the First Long-Acting Second-Generation Antipsychotic

Hyperinsulinemia in Psychiatric Patients Treated With Olanzapine

D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET

Risperidone Treatment of Tardive Dyskinesia and Dystonia

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles